Plus Therapeutics is a clinical-stage pharmaceutical company focused on the discovery, development, and delivery of treatments for patients battling cancer and rare diseases. Co.'s proprietary Nanomedicine platform provides improved delivery options and improved pharamacokinetics for a variety of drugs. Co.'s platform facilitates new delivery approaches and/or formulations for a variety of clinically proven therapies, potentially improving the safety, efficacy and convenience for patients and healthcare providers. Co.'s primary product candidate, DocePLUS, is a protein-stabilized PEGylated liposomal formulation of docetaxel, for which the process of preparation is patented. The PSTV stock yearly return is shown above.
The yearly return on the PSTV stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2018 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the PSTV annual return calculation with any dividends reinvested as applicable (on ex-dates).
|